Brief: Hungary Richter Says Canada Approves Vraylar For Treatment Of Bipolar Disorder

Gedeon Richter

27/04/2022 12:39

April 27 (Reuters) - Hungarian drug maker Richter says in
statement:
    * HEALTH CANADA APPROVES VRAYLAR (CARIPRAZINE) FOR TREATMENT
OF
BIPOLAR DISORDER AND SCHIZOPHRENIA IN ADULTS 
    * VRAYLAR IS BEING DEVELOPED JOINTLY BY ABBVIE AND RICHTER
WITH
ABBVIE RESPONSIBLE FOR COMMERCIALISATION IN US, CANADA, JAPAN,
TAIWAN AND SOME LATIN AMERICAN COUNTRIES

Source text for Eikon: [https://bet.hu/newkibdata/128713830/RCH220427ER01E.pdf
]
Further company coverage: [GDRB.BU ]

 (Reporting by Krisztina  Than)
 ((Krisztina.Than@thomsonreuters.com;))